<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art560.dtd?><?SourceDTD.Version 5.6.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_NMNI100837 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">New Microbes New Infect</journal-id><journal-id journal-id-type="iso-abbrev">New Microbes New Infect</journal-id><journal-title-group><journal-title>New Microbes and New Infections</journal-title></journal-title-group><issn pub-type="epub">2052-2975</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7785423</article-id><article-id pub-id-type="pii">S2052-2975(21)00001-9</article-id><article-id pub-id-type="doi">10.1016/j.nmni.2021.100837</article-id><article-id pub-id-type="publisher-id">100837</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial</subject></subj-group></article-categories><title-group><article-title>Oral probiotics in coronavirus disease 2019: connecting the gut&#x02013;lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Baindara</surname><given-names>P.</given-names></name><email>pbaindara@health.missouri.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Chakraborty</surname><given-names>R.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Holliday</surname><given-names>Z.M.</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Mandal</surname><given-names>S.M.</given-names></name><email>mandalsm@gmail.com</email><xref rid="aff4" ref-type="aff">4</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Schrum</surname><given-names>A.G.</given-names></name><email>schruma@health.missouri.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref><xref rid="cor3" ref-type="corresp">&#x02217;&#x02217;&#x02217;</xref></contrib><aff id="aff1"><label>1)</label>Department of Molecular Microbiology &#x00026; Immunology, School of Medicine, University of Missouri, Columbia, MO, USA</aff><aff id="aff2"><label>2)</label>Department of Biotechnology, North Bengal University, Darjeeling, India</aff><aff id="aff3"><label>3)</label>Pulmonary Disease, Critical Care Medicine, School of Medicine, University of Missouri, Columbia, MO, USA</aff><aff id="aff4"><label>4)</label>Central Research Facility, Indian Institute of Technology Kharagpur, Kharagpur, India</aff><aff id="aff5"><label>5)</label>Department of Surgery, School of Medicine, University of Missouri, Columbia, MO, USA</aff><aff id="aff6"><label>6)</label>Department of Biomedical, Biological, &#x00026; Chemical Engineering, College of Engineering, University of Missouri, Columbia, MO, USA</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label><bold>Corresponding author:</bold> P. Baindara, Department of Molecular Microbiology &#x00026; Immunology, School of Medicine, University of Missouri, Columbia, MO, USA. <email>pbaindara@health.missouri.edu</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label><bold>Corresponding author:</bold> S.M. Mandal, Central Research Facility, Indian Institute of Technology Kharagpur, Kharagpur, India. <email>mandalsm@gmail.com</email></corresp><corresp id="cor3"><label>&#x02217;&#x02217;&#x02217;</label><bold>Corresponding author:</bold> A. Schrum, Department of Molecular Microbiology &#x00026; Immunology, School of Medicine, University of Missouri, Columbia, MO, USA. <email>schruma@health.missouri.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>06</day><month>1</month><year>2021</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>3</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>06</day><month>1</month><year>2021</year></pub-date><volume>40</volume><elocation-id>100837</elocation-id><history><date date-type="received"><day>18</day><month>8</month><year>2020</year></date><date date-type="rev-recd"><day>12</day><month>12</month><year>2020</year></date><date date-type="accepted"><day>31</day><month>12</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2021 The Authors</copyright-statement><copyright-year>2021</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>Defined as helpful live bacteria that can provide medical advantages to the host when administered in tolerable amounts, oral probiotics might be worth considering as a possible preventive or therapeutic modality to mitigate coronavirus disease 2019 (COVID-19) symptom severity. This hypothesis stems from an emerging understanding of the gut&#x02013;lung axis wherein probiotic microbial species in the digestive tract can influence systemic immunity, lung immunity, and possibly viral pathogenesis and secondary infection co-morbidities. We review the principles underlying the gut&#x02013;lung axis, examples of probiotic-associated antiviral activities, and current clinical trials in COVID-19 based on oral probiotics.</p></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Probiotics are known as helpful live bacteria for medical advantages to the host when administered intolerable amounts.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">The study summarizes the embedded cross-road between gut and lung microbiota.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">Probiotics are significant solutions to improve gut health or dysbiosis created by viral infections like SARS-CoV-2.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">Evidence has also been given about extenuating inflammation and antiviral properties of probiotics.</p></list-item><list-item id="u0030"><p id="p0075">Probiotics can be an adjunctive treatment procedure to battle against COVID-19 and associated secondary infections.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Coronavirus disease 2019</kwd><kwd>gut&#x02013;lung axis</kwd><kwd>gut microbiome</kwd><kwd>probiotics</kwd><kwd>secondary infection</kwd><kwd>severe acute respiratory syndrome coronavirus 2</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Gut&#x02013;lung connectivity in infection and immunity</title><p id="p0030">The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses angiotensin converting enzyme 2 as the receptor for cell entry, which is highly expressed in gut and lung tissues that produce well-described symptoms in coronavirus disease 2019 (COVID-19) [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. In the gut, proximal and distal enterocytes are targets [<xref rid="bib3" ref-type="bibr">3</xref>], and both the receptor and these cell types are known to be pathologically connected with intestinal inflammation and diarrhoea [<xref rid="bib4" ref-type="bibr">4</xref>]. Nausea and diarrhoea are reported to be primary symptoms of COVID-19 even before the development of fever and respiratory symptoms, whereas abdominal pain continues to be reported frequently in patients admitted to intensive care [<xref rid="bib5" ref-type="bibr">5</xref>]. The most severe cases of COVID-19 often involve pneumonia followed by acute respiratory distress syndrome [<xref rid="bib6" ref-type="bibr">6</xref>], involving hypoxaemic respiratory distress concurrent with lung neutrophilia, mucus and fluid accumulation in bronchi, and bronchiectasis [<xref rid="bib7" ref-type="bibr">7</xref>].</p><p id="p0035">Besides the shared trait of direct viral targeting in both gut and lung, the two tissues share a relationship influencing inflammatory and immune responses via the gut&#x02013;lung axis that can be responsive to probiotics through effects on commensal microbial flora. From birth, both gut and lungs share exposure to microbes through the oral route, a process that over time seeds a quasi-stable and complex gut flora, with growing evidence for a much lower level of microbial species in the lung that are different between the upper and lower respiratory tracts [<xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>]. Focusing on gut flora, microbe interactions and their products influence innate and adaptive immune signals and cells locally, systemically, and specifically in the lungs, where it has been shown that the gut microbiome affects susceptibility to asthma, lung allergic responses and chronic obstructive pulmonary disease [<xref rid="bib11" ref-type="bibr">11</xref>,<xref rid="bib12" ref-type="bibr">12</xref>]. Various insults can cause dysbiosis of the gut microbial flora, including antibiotic treatment or pathogenic infection, which can result in increased gut permeability, in turn leading to microbial translocation and systemic dispersal of toxins and inflammatory products to the circulatory system [<xref rid="bib13" ref-type="bibr">13</xref>]. Therefore, whether due to pre-existing differences in gut flora, or differences induced upon infection, it is conceivable that the microbiome may influence differences in the inflammatory response between patients that could correspond with COVID-19 severity.</p></sec><sec id="sec2"><title>Probiotics improving anti-viral responses</title><p id="p0040">Oral probiotics are live bacteria that can improve gut health in homeostasis, and can exhibit antiviral effects [<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib15" ref-type="bibr">15</xref>] via the gut&#x02013;lung axis [<xref rid="bib16" ref-type="bibr">16</xref>]. Upon delivery, probiotics are understood to adjust the crosstalk between commensal microbes and the mucosal immune framework, and in this way alter the basal and induced inflammatory balance in response to viral infections [<xref rid="bib14" ref-type="bibr">14</xref>]. Regarding upper respiratory tract disease, some probiotics have shown anti-viral protective and therapeutic effects, lessening the severity and extent of tissue damage from infection and inflammation [<xref rid="bib17" ref-type="bibr">17</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. Diminished plasma titres of Epstein&#x02013;Barr virus and antibody titres against cytomegalovirus were observed in upper respiratory tract infections upon treatment with the lactic acid-producing bacterium <italic>Lactobacillus casei</italic>, by a mechanism dependent on Toll-like receptors [<xref rid="bib19" ref-type="bibr">19</xref>]. Another probiotic bacterium, <italic>Lactococcus lactis</italic> JCM 5805, was demonstrated to have antiviral activity against influenza virus infection and to activate plasmacytoid dendritic cells using Toll-like receptor 9 [<xref rid="bib20" ref-type="bibr">20</xref>]. Treatment with the probiotic <italic>Bifidobacterium lactis</italic> HN019 was reported to increase mononuclear leucocyte recruitment and elevate phagocytic and lytic activity [<xref rid="bib21" ref-type="bibr">21</xref>]. The probiotic impact of <italic>Lactobacillus gasseri</italic> has been shown against respiratory syncytial virus infection in mice by a significant reduction of viral titre in the lungs along with decreases in several pulmonary pro-inflammatory cytokines, but increases in interferon types I and II [<xref rid="bib22" ref-type="bibr">22</xref>]. Lactic acid-producing bacteria (LAB) have been used in probiotic settings via nasal and oral application, where modulation of cytokine profiles was associated with protection against respiratory syncytial virus [<xref rid="bib23" ref-type="bibr">23</xref>,<xref rid="bib24" ref-type="bibr">24</xref>], and wider application for respiratory infections has been suggested [<xref rid="bib25" ref-type="bibr">25</xref>]. A clinical report in neonates demonstrated that probiotic treatment in early life was associated with decreased rates of subsequent respiratory tract infections [<xref rid="bib26" ref-type="bibr">26</xref>]. Up to this point, many clinical trials have investigated the potential impacts of probiotics on viral infections (<xref rid="tbl1" ref-type="table">Table&#x000a0;1</xref>), with some current trials exploring the effectiveness of probiotics in the context of COVID-19 (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>).<table-wrap position="float" id="tbl1"><label>Table&#x000a0;1</label><caption><p>Probiotics, targeted viral infections, immunostimulatory mode of action, reported medicinal effects and supporting references</p></caption><alt-text id="alttext0015">Table&#x000a0;1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Probiotic bacteria (strain)</th><th>Viral infection</th><th>Immunostimulatory mode of action</th><th>Reported medicinal effects</th><th>Ref.</th></tr></thead><tbody><tr><td><italic>Lactobacillus brevis</italic> (KB290)</td><td>Influenza virus</td><td>Increased IFN-&#x003b1; production and augmentation of influenza-virus-specific immunoglobulin A production</td><td>Reduced risk of infection</td><td>[<xref rid="bib61" ref-type="bibr">61</xref>]</td></tr><tr><td><italic>Lactobacillus rhamnosus</italic> (GG)</td><td>Influenza virus</td><td>Increased IFN-&#x003b3; production in serum</td><td>Reduced risk of infection</td><td>[<xref rid="bib62" ref-type="bibr">62</xref>]</td></tr><tr><td><italic>Lactobacillus bulgaricus</italic> (OLL1073R-1) and <italic>Streptococcus thermophiles</italic></td><td>Rhinovirus</td><td>Increased IFN-&#x003b3; production in serum</td><td>No significant difference</td><td>[<xref rid="bib63" ref-type="bibr">63</xref>]</td></tr><tr><td><italic>Lactobacillus rhamnosus</italic> (GG)</td><td>Rhinovirus</td><td>Not determined</td><td>Reduced incidence of respiratory tract infections (RTIs)</td><td>[<xref rid="bib64" ref-type="bibr">64</xref>]</td></tr><tr><td><italic>Lactobacillus rhamnosus</italic> (GG)</td><td>Rhinovirus</td><td>Not determined</td><td>Reduced incidence of RTIs</td><td>[<xref rid="bib65" ref-type="bibr">65</xref>]</td></tr><tr><td><italic>Lactobacillus rhamnosus</italic> (GG)</td><td>Rhinovirus, respiratory syncytial virus, parainfluenza virus 1</td><td>Not determined</td><td>Reduced number of days with symptoms</td><td>[<xref rid="bib66" ref-type="bibr">66</xref>]</td></tr><tr><td><italic>Lactobacillus casei</italic> (DN-114001)</td><td>Rhinopharyngitis, influenza virus</td><td>Increased expression of defensins</td><td>Decreased duration of common infectious diseases</td><td>[<xref rid="bib67" ref-type="bibr">67</xref>]</td></tr><tr><td><italic>Lactobacillus rhamnosus</italic> (M21)</td><td>Influenza virus</td><td>Increased IFN-&#x003b3; and interleukin-2</td><td>Increased host resistance against influenza virus infection</td><td>[<xref rid="bib68" ref-type="bibr">68</xref>]</td></tr><tr><td><italic>Bacillus subtilis</italic> (OKB105)</td><td>Transmissible gastroenteritis virus</td><td>Inhibition of virus entry by competing with viral entry receptors</td><td>Reduced viral entry <italic>in&#x000a0;vitro</italic></td><td>[<xref rid="bib69" ref-type="bibr">69</xref>]</td></tr><tr><td><italic>Bifidobacterium animalis</italic></td><td>Rhinovirus</td><td>Inhibition of CXCL8 response upon viral infection</td><td>Decreased viral titres in nasal lavage and viral shedding in the nasal secretions</td><td>[<xref rid="bib70" ref-type="bibr">70</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations:&#x000a0;COVID-19, coronavirus disease 2019; IFN, interferon; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2"><label>Table&#x000a0;2</label><caption><p>Current clinical trials of probiotics in coronavirus disease 2019 registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0010">ClinicalTrials.gov</ext-link></p></caption><alt-text id="alttext0020">Table&#x000a0;2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>ClinicalTrials.gov identifier</th><th>Study title</th><th>Probiotic bacteria (strain)</th><th>Procedure synopsis</th></tr></thead><tbody><tr><td>NCT04458519</td><td>Efficacy of intranasal probiotic treatment to reduce severity of symptoms in COVID-19 infection</td><td><italic>Lactococcus lactis</italic> (W136)</td><td>Nasal irrigation with probiorinse</td></tr><tr><td>NCT04390477</td><td>Study to evaluate the effect of a probiotic in COVID-19</td><td>Not revealed</td><td>Dietary supplementation</td></tr><tr><td>NCT04366180</td><td>Evaluation of probiotic <italic>Lactobacillus coryniformis</italic> K8 on COVID-19 prevention in health-care workers</td><td><italic>Lactobacillus coryniformis</italic> (K8)</td><td>Dietary supplementation</td></tr><tr><td>NCT04517422</td><td>Efficacy of <italic>Lactobacillus plantarum</italic> and <italic>Pediococcus acidilactici</italic> in adults with SARS-CoV-2 and COVID-19</td><td><italic>Lactobacillus plantarum</italic> (CECT7481) <italic>Lactobacillus plantarum</italic> (CECT7484) <italic>Lactobacillus plantarum</italic> (CECT7485) <italic>Pediococcus acidilactici</italic> (CECT7483)</td><td>Not revealed</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3"><title>Anti-inflammatory probiotics and COVID-19</title><p id="p0045">Some probiotics enhance regulatory T-cell activity and reduce pro-inflammatory cytokine production [<xref rid="bib27" ref-type="bibr">[27]</xref>, <xref rid="bib28" ref-type="bibr">[28]</xref>, <xref rid="bib29" ref-type="bibr">[29]</xref>, <xref rid="bib30" ref-type="bibr">[30]</xref>]. For example, the anti-inflammatory activity of <italic>Weissella cibaaria</italic> (JW15) was assessed upon lipopolysaccharide challenge in mouse macrophages, where the probiotic was associated with reduced induction of interleukin-1&#x003b2; (IL-1&#x003b2;), IL-6 and tumour necrosis factor-&#x003b1; (TNF-&#x003b1;). When the stimulus was changed to heat-killed JW15, the same study observed diminished production of nitric oxide and prostaglandin E<sub>2</sub> using down-regulation of inducible nitric oxide synthase and cyclooxygenase 2 [<xref rid="bib31" ref-type="bibr">31</xref>]. Human commensal strains <italic>Lactobacillus rhamnosus</italic> GG and GR-1 appear capable of anti-inflammatory effects using down-regulation of TNF-&#x003b1; production in human monocytes and mouse macrophages [<xref rid="bib32" ref-type="bibr">32</xref>].</p><p id="p0050">Evidence to date suggests that probiotics with anti-inflammatory or immunomodulatory properties might be predicted to have the most beneficial potential to prevent or alleviate COVID-19 symptoms (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>). Clinical investigations along with increasing data worldwide suggest that cytokine storm causing hyper-inflammation in the respiratory tract has an apparent causal, positive correlation with COVID-19 disease severity [<xref rid="bib33" ref-type="bibr">33</xref>]. Blood plasma analysis of 41 individuals with confirmed COVID-19 in Wuhan, China revealed increased levels of various cytokines including IL-1&#x003b2;, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor, granulocyte colony-stimulating factor, granulocyte&#x02013;macrophage colony-stimulating factor, interferon-&#x003b3;, IFN-&#x003b3;-inducible protein-10, monocyte chemoattractant protein-1, macrophage inflammatory protein-1A and -1B, platelet-derived growth factor, TNF-&#x003b1;, and vascular endothelial growth factor in people with COVID-19 compared with healthy individuals [<xref rid="bib34" ref-type="bibr">34</xref>]. Given these observations, inhibiting or down-regulating this cytokine response may create a healthier immune activation balance to reduce inflammatory symptoms while maintaining adaptive immune engagement against SARS-COV-2 (<xref rid="fig1" ref-type="fig">Fig.&#x000a0;1</xref>).<fig id="fig1"><label>Fig.&#x000a0;1</label><caption><p>Step-by-step progressive schematic illustration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and involvement of the gut&#x02013;lung axis. Potential targets or steps at which the action of probiotics might mitigate coronavirus disease 2019 (COVID-19) are represented, with specific mechanisms of action possible for probiotics highlighted in yellow.</p></caption><alt-text id="alttext0010">Fig.&#x000a0;1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0055">Because probiotics have been studied and recommended in the context of respiratory tract infections, the hypothesis emerges that probiotics might play a positive role against COVID-19. For example, gut dysbiosis during influenza virus infection has been shown to worsen lung pathology and aggravate secondary pneumococcal lung infections [<xref rid="bib35" ref-type="bibr">35</xref>,<xref rid="bib36" ref-type="bibr">36</xref>], and gut microbiota dysbiosis has been reported in some COVID-19 patients concurrent with decreases in natural probiotic bacterial species including <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> [<xref rid="bib37" ref-type="bibr">37</xref>]. Clinical transcriptome analyses from COVID-19 patients have also indicated a gastrointestinal disease course and potential systemic crosstalk between gut and lungs during SARS-CoV-2 infection [<xref rid="bib38" ref-type="bibr">38</xref>]. Sufficient rationale has accumulated such that clinical trials of probiotics against COVID-19 are already underway, so far emphasizing probiotics with expected anti-inflammatory effects in the gut&#x02013;lung axis (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>).</p></sec><sec id="sec4"><title>Possible roles of probiotic antimicrobial peptides</title><p id="p0060">Probiotics can produce direct antimicrobial effects via metabolites and antimicrobial peptides, including bacteriocins, which could potentially contribute beneficial effects against SARS-CoV-2 as a membranous envelope virus. A species of genus <italic>Lactococcus</italic> is in a current clinical trial for probiotic activity against COVID-19 (<xref rid="tbl2" ref-type="table">Table&#x000a0;2</xref>), and this genus includes LAB whose anti-viral effects may be due in part to secreted metabolites and an enormous number of bacteriocins [<xref rid="bib39" ref-type="bibr">39</xref>], one class of antimicrobial peptides considered to be guard peptides [<xref rid="bib40" ref-type="bibr">40</xref>]. Nisin is one of the most widely studied bacteriocins and has been approved for many years as an FDA endorsed food additive. Antimicrobial peptides that can be expressed by LAB appear to contribute to probiotic antiviral effects against influenza A virus and other respiratory viruses [<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib42" ref-type="bibr">42</xref>]. From a different genus, the probiotic <italic>Bacillus subtilis</italic> strain was shown to produce an antiviral peptide, P18, which inhibited influenza infection both <italic>in&#x000a0;vitro</italic> and <italic>in&#x000a0;vivo</italic> [<xref rid="bib43" ref-type="bibr">43</xref>]. Examples of probiotic lipopeptides include lipopeptide detergent-12, subtilisin, curvacin A, sakacin P and lactococcin Gb, which are well described extracellularly expressed products that may block the virus&#x02013;cell fusion process or other steps of viral entry by mechanisms involving their amphiphilic nature [<xref rid="bib44" ref-type="bibr">44</xref>,<xref rid="bib45" ref-type="bibr">45</xref>]. If such probiotic products were to have direct access to SARS-CoV-2 virions in the gut, or perhaps in the lungs through disease-induced dysbiosis, gut permeability, and dissemination, it can be hypothesized that direct antiviral effects may be possible.</p></sec><sec id="sec5"><title>Possible probiotic protection against infections secondary to SARS-CoV-2</title><p id="p0065">Because probiotics can mitigate problems of dysbiosis, inflammation and immune function, and can include direct antimicrobial activities, there may be the potential for a positive contribution against secondary infection co-morbidities in COVID-19. New evidence is emerging that infections secondary to SARS-CoV-2 might contribute to COVID-19 pathology or severity [<xref rid="bib46" ref-type="bibr">[46]</xref>, <xref rid="bib47" ref-type="bibr">[47]</xref>, <xref rid="bib48" ref-type="bibr">[48]</xref>, <xref rid="bib49" ref-type="bibr">[49]</xref>]. Although an early study suggested relatively little concern across the COVID-19 patient population [<xref rid="bib50" ref-type="bibr">50</xref>], recent reports are finding increased secondary infections in hospitalized individuals with severe disease, observations that may have some association with immunosuppressive drugs in current treatment regimens [<xref rid="bib51" ref-type="bibr">[51]</xref>, <xref rid="bib52" ref-type="bibr">[52]</xref>, <xref rid="bib53" ref-type="bibr">[53]</xref>]. Outside the COVID-19 context, application of the probiotic strains <italic>Lactobacillus rhamnosus</italic> GG, <italic>Bacillus subtilis</italic> and <italic>Enterococcus faecalis</italic> during clinical trials, showed a significant improvement in patients with ventilator-associated pneumonia, including pathogens of various types, compared with placebo treatment [<xref rid="bib54" ref-type="bibr">54</xref>,<xref rid="bib55" ref-type="bibr">55</xref>]. In general, probiotic strains themselves, including LAB strains, are well known to be non-pathogenic and non-immunogenic, and therefore are considered safe and not a source of potential secondary infections, themselves [<xref rid="bib56" ref-type="bibr">56</xref>]. Along with protective effects reported against influenza A virus, LAB have been reported to promote heterotypic immunity to secondary infections [<xref rid="bib57" ref-type="bibr">57</xref>,<xref rid="bib58" ref-type="bibr">58</xref>]. Furthermore, probiotics have been reported to provide some protection against biofilm-forming pathogens in the respiratory tract [<xref rid="bib59" ref-type="bibr">59</xref>,<xref rid="bib60" ref-type="bibr">60</xref>]. As secondary infections may rise to more prominence in COVID-19, perhaps commensurate with increasing anti-inflammatory regimens, treatment options that include probiotics may present an even more attractive modality that merits further investigation and attention in clinical trials.</p></sec><sec id="sec7"><title>Conflict of interest</title><p id="p0080">There is no conflict of interest.</p></sec><sec id="sec6"><title>Funding</title><p id="p0070">PB and AGS were supported by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100007165</institution-id><institution>University of Missouri</institution></institution-wrap></funding-source> Biomedical Innovation recruitment funds, and AGS was supported by <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source> grant R01GM103841.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Bourgonje</surname><given-names>A.R.</given-names></name><name><surname>Abdulle</surname><given-names>A.E.</given-names></name><name><surname>Timens</surname><given-names>W.</given-names></name><name><surname>Hillebrands</surname><given-names>J.L.</given-names></name><name><surname>Navis</surname><given-names>G.J.</given-names></name><name><surname>Gordijn</surname><given-names>S.J.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)</article-title><source>J&#x000a0;Pathol</source><volume>251</volume><year>2020</year><fpage>228</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1002/path.5471</pub-id><pub-id pub-id-type="pmid">32418199</pub-id></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Letko</surname><given-names>M.</given-names></name><name><surname>Marzi</surname><given-names>A.</given-names></name><name><surname>Munster</surname><given-names>V.</given-names></name></person-group><article-title>Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses</article-title><source>Nat Microbiol</source><volume>5</volume><year>2020</year><fpage>562</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0688-y</pub-id><pub-id pub-id-type="pmid">32094589</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>C.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name></person-group><article-title>Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus</article-title><source>Gut</source><volume>69</volume><year>2020</year><fpage>1141</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-320832</pub-id><pub-id pub-id-type="pmid">32102928</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Perlot</surname><given-names>T.</given-names></name><name><surname>Rehman</surname><given-names>A.</given-names></name><name><surname>Trichereau</surname><given-names>J.</given-names></name><name><surname>Ishiguro</surname><given-names>H.</given-names></name><name><surname>Paolino</surname><given-names>M.</given-names></name></person-group><article-title>ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation</article-title><source>Nature</source><volume>487</volume><year>2012</year><fpage>477</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">22837003</pub-id></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>C.</given-names></name><name><surname>Kaushal</surname><given-names>S.</given-names></name><name><surname>Yeo</surname><given-names>D.</given-names></name></person-group><article-title>Enteric involvement of coronaviruses: is faecal&#x02013;oral transmission of SARS-CoV-2 possible?</article-title><source>Lancet Gastroenterol Hepatol</source><volume>5</volume><year>2020</year><fpage>335</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/S2468-1253(20)30048-0</pub-id><pub-id pub-id-type="pmid">32087098</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>E.</given-names></name><name><surname>Beitler</surname><given-names>J.R.</given-names></name><name><surname>Brochard</surname><given-names>L.</given-names></name><name><surname>Calfee</surname><given-names>C.S.</given-names></name><name><surname>Ferguson</surname><given-names>N.D.</given-names></name><name><surname>Slutsky</surname><given-names>A.S.</given-names></name></person-group><article-title>COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?</article-title><source>Lancet Respir Med</source><volume>8</volume><year>2020</year><fpage>816</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(20)30304-0</pub-id><pub-id pub-id-type="pmid">32645311</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J jin</given-names></name><name><surname>Dong</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>Y yuan</given-names></name><name><surname>Yuan</surname><given-names>Y dong</given-names></name><name><surname>Yang</surname><given-names>Y bin</given-names></name><name><surname>Yan</surname><given-names>Y qin</given-names></name></person-group><article-title>Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China</article-title><source>Allergy Eur J Allergy Clin Immunol</source><volume>75</volume><year>2020</year><fpage>1730</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1111/all.14238</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Grier</surname><given-names>A.</given-names></name><name><surname>McDavid</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Qiu</surname><given-names>X.</given-names></name><name><surname>Java</surname><given-names>J.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>S.</given-names></name></person-group><article-title>Neonatal gut and respiratory microbiota: coordinated development through time and space</article-title><source>Microbiome</source><volume>6</volume><year>2018</year><fpage>193</fpage><pub-id pub-id-type="pmid">30367675</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Madan</surname><given-names>J.C.</given-names></name><name><surname>Koestle</surname><given-names>D.C.</given-names></name><name><surname>Stanton</surname><given-names>B.A.</given-names></name><name><surname>Davidson</surname><given-names>L.</given-names></name><name><surname>Moulton</surname><given-names>L.A.</given-names></name><name><surname>Housman</surname><given-names>M.L.</given-names></name></person-group><article-title>Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures</article-title><source>MBio</source><volume>3</volume><year>2012</year><comment>e00251-12</comment></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Han</surname><given-names>N.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name></person-group><article-title>16S rDNA analysis of the effect of fecal microbiota transplantation on pulmonary and intestinal flora</article-title><source>3 Biotech</source><volume>7</volume><year>2017</year><fpage>370</fpage></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Enaud</surname><given-names>R.</given-names></name><name><surname>Prevel</surname><given-names>R.</given-names></name><name><surname>Ciarlo</surname><given-names>E.</given-names></name><name><surname>Beaufils</surname><given-names>F.</given-names></name><name><surname>Wie&#x000eb;rs</surname><given-names>G.</given-names></name><name><surname>Guery</surname><given-names>B.</given-names></name></person-group><article-title>The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks</article-title><source>Front Cell Infect Microbiol</source><volume>10</volume><year>2020</year><pub-id pub-id-type="doi">10.3389/fcimb.2020.00009</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>A.T.</given-names></name><name><surname>Marsland</surname><given-names>B.J.</given-names></name></person-group><article-title>Microbes, metabolites, and the gut&#x02013;lung axis</article-title><source>Mucosal Immunol</source><volume>12</volume><year>2019</year><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1038/s41385-019-0160-6</pub-id><pub-id pub-id-type="pmid">30976087</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group><article-title>Crossing barriers: infections of the lung and the gut</article-title><source>Mucosal Immunol</source><volume>2</volume><year>2009</year><fpage>100</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1038/mi.2008.79</pub-id><pub-id pub-id-type="pmid">19129753</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Kanauchi</surname><given-names>O.</given-names></name><name><surname>Andoh</surname><given-names>A.</given-names></name><name><surname>AbuBakar</surname><given-names>S.</given-names></name><name><surname>Yamamoto</surname><given-names>N.</given-names></name></person-group><article-title>Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems</article-title><source>Curr Pharm Des</source><volume>24</volume><year>2018</year><fpage>710</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.2174/1381612824666180116163411</pub-id><pub-id pub-id-type="pmid">29345577</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Tiwari</surname><given-names>S.K.</given-names></name><name><surname>Dicks</surname><given-names>L.M.T.</given-names></name><name><surname>Popov</surname><given-names>I.V.</given-names></name><name><surname>Karaseva</surname><given-names>A.</given-names></name><name><surname>Ermakov</surname><given-names>A.M.</given-names></name><name><surname>Suvorov</surname><given-names>A.</given-names></name></person-group><article-title>Probiotics at war against viruses: what is missing from the picture?</article-title><source>Front Microbiol</source><volume>11</volume><year>2020</year><pub-id pub-id-type="doi">10.3389/fmicb.2020.01877</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>S.</given-names></name><name><surname>Mande</surname><given-names>S.S.</given-names></name></person-group><article-title>Diet, microbiota and gut&#x02013;lung connection</article-title><source>Front Microbiol</source><volume>9</volume><year>2018</year><pub-id pub-id-type="doi">10.3389/fmicb.2018.02147</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Long</surname><given-names>J.D.</given-names></name><name><surname>Morris</surname><given-names>A.</given-names></name></person-group><article-title>Probiotics in preventing acute upper respiratory tract infections</article-title><source>Am J Nurs</source><volume>117</volume><year>2017</year><fpage>69</fpage><pub-id pub-id-type="doi">10.1097/01.NAJ.0000527494.16987.1e</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Tapiovaara</surname><given-names>L.</given-names></name><name><surname>Lehtoranta</surname><given-names>L.</given-names></name><name><surname>Poussa</surname><given-names>T.</given-names></name><name><surname>M&#x000e4;kivuokko</surname><given-names>H.</given-names></name><name><surname>Korpela</surname><given-names>R.</given-names></name><name><surname>Pitk&#x000e4;ranta</surname><given-names>A.</given-names></name></person-group><article-title>Absence of adverse events in healthy individuals using probiotics &#x02013; analysis of six randomised studies by one study group</article-title><source>Benef Microbe</source><volume>7</volume><year>2016</year><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.3920/BM2015.0096</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Pimentel-Nunes</surname><given-names>P.</given-names></name><name><surname>Soares</surname><given-names>J.B.</given-names></name><name><surname>Roncon-Albuquerque</surname><given-names>R.</given-names></name><name><surname>Dinis-Ribeiro</surname><given-names>M.</given-names></name><name><surname>Leite-Moreira</surname><given-names>A.F.</given-names></name></person-group><article-title>Toll-like receptors as therapeutic targets in gastrointestinal diseases</article-title><source>Expert Opin Ther Targets</source><volume>14</volume><year>2010</year><fpage>347</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1517/14728221003642027</pub-id><pub-id pub-id-type="pmid">20146632</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>T.</given-names></name><name><surname>Kanayama</surname><given-names>M.</given-names></name><name><surname>Haida</surname><given-names>M.</given-names></name><name><surname>Fujimoto</surname><given-names>S.</given-names></name><name><surname>Oroguchi</surname><given-names>T.</given-names></name><name><surname>Sata</surname><given-names>K.</given-names></name></person-group><article-title>Lactococcus lactis JCM5805 activates anti-viral immunity and reduces symptoms of common cold and influenza in healthy adults in a randomized controlled trial</article-title><source>J&#x000a0;Funct Foods</source><volume>24</volume><year>2016</year><fpage>492</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1016/j.jff.2016.03.035</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Gill</surname><given-names>H.S.</given-names></name><name><surname>Rutherfurd</surname><given-names>K.J.</given-names></name><name><surname>Cross</surname><given-names>M.L.</given-names></name><name><surname>Gopal</surname><given-names>P.K.</given-names></name></person-group><article-title>Enhancement of immunity in the elderly by dietary supplementation with the probiotic <italic>Bifidobactedum lactis</italic> HN019</article-title><source>Am J Clin Nutr</source><volume>74</volume><year>2001</year><fpage>833</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1093/ajcn/74.6.833</pub-id><pub-id pub-id-type="pmid">11722966</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Eguchi</surname><given-names>K.</given-names></name><name><surname>Fujitani</surname><given-names>N.</given-names></name><name><surname>Nakagawa</surname><given-names>H.</given-names></name><name><surname>Miyazaki</surname><given-names>T.</given-names></name></person-group><article-title>Prevention of respiratory syncytial virus infection with probiotic lactic acid bacterium <italic>Lactobacillus gasseri</italic> SBT2055</article-title><source>Sci Rep</source><volume>9</volume><year>2019</year><pub-id pub-id-type="doi">10.1038/s41598-019-39602-7</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Tomosada</surname><given-names>Y.</given-names></name><name><surname>Chiba</surname><given-names>E.</given-names></name><name><surname>Zelaya</surname><given-names>H.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Tsukida</surname><given-names>K.</given-names></name><name><surname>Kitazawa</surname><given-names>H.</given-names></name></person-group><article-title>Nasally administered <italic>Lactobacillus rhamnosus</italic> strains differentially modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection</article-title><source>BMC Immunol</source><volume>14</volume><year>2013</year><fpage>40</fpage><pub-id pub-id-type="doi">10.1186/1471-2172-14-40</pub-id><pub-id pub-id-type="pmid">23947615</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Villena</surname><given-names>J.</given-names></name><name><surname>Chiba</surname><given-names>E.</given-names></name><name><surname>Tomosada</surname><given-names>Y.</given-names></name><name><surname>Salva</surname><given-names>S.</given-names></name><name><surname>Marranzino</surname><given-names>G.</given-names></name><name><surname>Kitazawa</surname><given-names>H.</given-names></name></person-group><article-title>Orally administered <italic>Lactobacillus rhamnosus</italic> modulates the respiratory immune response triggered by the viral pathogen-associated molecular pattern poly(I:C)</article-title><source>BMC Immunol</source><volume>13</volume><year>2012</year><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/1471-2172-13-53</pub-id><pub-id pub-id-type="pmid">22989047</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Villena</surname><given-names>J.</given-names></name><name><surname>Oliveira</surname><given-names>M.L.S.</given-names></name><name><surname>Ferreira</surname><given-names>P.C.D.</given-names></name><name><surname>Salva</surname><given-names>S.</given-names></name><name><surname>Alvarez</surname><given-names>S.</given-names></name></person-group><article-title>Lactic acid bacteria in the prevention of pneumococcal respiratory infection: future opportunities and challenges</article-title><source>Int Immunopharmacol</source><volume>11</volume><year>2011</year><fpage>1633</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2011.06.004</pub-id><pub-id pub-id-type="pmid">21708293</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Luoto</surname><given-names>R.</given-names></name><name><surname>Ruuskanen</surname><given-names>O.</given-names></name><name><surname>Waris</surname><given-names>M.</given-names></name><name><surname>Kalliom&#x000e4;ki</surname><given-names>M.</given-names></name><name><surname>Salminen</surname><given-names>S.</given-names></name><name><surname>Isolauri</surname><given-names>E.</given-names></name></person-group><article-title>Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial</article-title><source>J&#x000a0;Allergy Clin Immunol</source><volume>133</volume><year>2014</year><fpage>405</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2013.08.020</pub-id><pub-id pub-id-type="pmid">24131826</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>F.</given-names></name><name><surname>Polk</surname><given-names>D.B.</given-names></name></person-group><article-title>Probiotics and immune health</article-title><source>Curr Opin Gastroenterol</source><volume>27</volume><year>2011</year><fpage>496</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1097/MOG.0b013e32834baa4d</pub-id><pub-id pub-id-type="pmid">21897224</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Martin Manuel</surname><given-names>P.</given-names></name><name><surname>Elena</surname><given-names>B.</given-names></name><name><surname>Carolina</surname><given-names>M.G.</given-names></name><name><surname>Gabriela</surname><given-names>P.</given-names></name></person-group><article-title>Oral probiotics supplementation can stimulate the immune system in a stress process</article-title><source>J&#x000a0;Nutr Intermed Metab</source><volume>8</volume><year>2017</year><fpage>29</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jnim.2017.06.001</pub-id></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Plaza-D&#x000ed;az</surname><given-names>J.</given-names></name><name><surname>Ruiz-Ojeda</surname><given-names>F.J.</given-names></name><name><surname>Vilchez-Padial</surname><given-names>L.M.</given-names></name><name><surname>Gil</surname><given-names>A.</given-names></name></person-group><article-title>Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases</article-title><source>Nutrients</source><volume>9</volume><year>2017</year><fpage>555</fpage><pub-id pub-id-type="doi">10.3390/nu9060555</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>N.S.</given-names></name><name><surname>Joung</surname><given-names>J.Y.</given-names></name><name><surname>Lee</surname><given-names>J.Y.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name></person-group><article-title>Probiotic and anti-inflammatory potential of <italic>Lactobacillus rhamnosus</italic> 4B15 and <italic>Lactobacillus gasseri</italic> 4M13 isolated from infant feces</article-title><source>PLoS One</source><volume>13</volume><year>2018</year><fpage>e0192021</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0192021</pub-id><pub-id pub-id-type="pmid">29444150</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>H.S.</given-names></name><name><surname>Lee</surname><given-names>N.K.</given-names></name><name><surname>Choi</surname><given-names>A.J.</given-names></name><name><surname>Choe</surname><given-names>J.S.</given-names></name><name><surname>Bae</surname><given-names>C.H.</given-names></name><name><surname>Paik</surname><given-names>H.D.</given-names></name></person-group><article-title>Anti-inflammatory potential of probiotic strain <italic>Weissella cibaria</italic> JW15 isolated from kimchi through regulation of NF-&#x003ba;B and MAPKs pathways in LPS-induced RAW 264.7 cells</article-title><source>J&#x000a0;Microbiol Biotechnol</source><volume>19</volume><year>2019</year><fpage>1022</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.4014/jmb.1903.03014</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.O.</given-names></name><name><surname>Sheikh</surname><given-names>H.I.</given-names></name><name><surname>Ha</surname><given-names>S.D.</given-names></name><name><surname>Martins</surname><given-names>A.</given-names></name><name><surname>Reid</surname><given-names>G.</given-names></name></person-group><article-title>G-CSF-mediated inhibition of JNK is a key mechanism for <italic>Lactobacillus rhamnosus</italic>-induced suppression of TNF production in macrophages</article-title><source>Cell Microbiol</source><volume>8</volume><year>2006</year><fpage>1958</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1111/j.1462-5822.2006.00763.x</pub-id><pub-id pub-id-type="pmid">16889627</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Ragab</surname><given-names>D.</given-names></name><name><surname>Salah Eldin</surname><given-names>H.</given-names></name><name><surname>Taeimah</surname><given-names>M.</given-names></name><name><surname>Khattab</surname><given-names>R.</given-names></name><name><surname>Salem</surname><given-names>R.</given-names></name></person-group><article-title>The COVID-19 cytokine storm; what we know so far</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><fpage>1446</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.01446</pub-id><pub-id pub-id-type="pmid">32612617</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Sencio</surname><given-names>V.</given-names></name><name><surname>Barthelemy</surname><given-names>A.</given-names></name><name><surname>Tavares</surname><given-names>L.P.</given-names></name><name><surname>Machado</surname><given-names>M.G.</given-names></name><name><surname>Soulard</surname><given-names>D.</given-names></name><name><surname>Cuinat</surname><given-names>C.</given-names></name></person-group><article-title>Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production</article-title><source>Cell Rep</source><volume>30</volume><year>2020</year><fpage>2934</fpage><lpage>2947</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2020.02.013</pub-id><pub-id pub-id-type="pmid">32130898</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Budden</surname><given-names>K.F.</given-names></name><name><surname>Gellatly</surname><given-names>S.L.</given-names></name><name><surname>Wood</surname><given-names>D.L.A.</given-names></name><name><surname>Cooper</surname><given-names>M.A.</given-names></name><name><surname>Morrison</surname><given-names>M.</given-names></name><name><surname>Hugenholtz</surname><given-names>P.</given-names></name></person-group><article-title>Emerging pathogenic links between microbiota and the gut-lung axis</article-title><source>Nat Rev Microbiol</source><volume>15</volume><year>2017</year><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2016.142</pub-id><pub-id pub-id-type="pmid">27694885</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="book" id="sref37"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Ni</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name></person-group><chapter-title>Management of corona virus disease-19 (COVID-19): the Zhejiang experience</chapter-title><year>2020</year><publisher-name>Zhejiang Da Xue Xue Bao Yi Xue Ban</publisher-name><comment>49:147&#x02013;157</comment></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>J.</given-names></name><name><surname>Young</surname><given-names>B.E.</given-names></name><name><surname>Ong</surname><given-names>S.</given-names></name></person-group><article-title>COVID-19 in gastroenterology: a clinical perspective</article-title><source>Gut</source><volume>69</volume><year>2020</year><fpage>1144</fpage><lpage>1145</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-321051</pub-id><pub-id pub-id-type="pmid">32198152</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Al Kassaa</surname><given-names>I.</given-names></name><name><surname>Hober</surname><given-names>D.</given-names></name><name><surname>Hamze</surname><given-names>M.</given-names></name><name><surname>Chihib</surname><given-names>N.E.</given-names></name><name><surname>Drider</surname><given-names>D.</given-names></name></person-group><article-title>Antiviral potential of lactic acid bacteria and their bacteriocins</article-title><source>Probiotics Antimicrob Proteins</source><volume>6</volume><year>2014</year><fpage>177</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1007/s12602-014-9162-6</pub-id><pub-id pub-id-type="pmid">24880436</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Cotter</surname><given-names>P.D.</given-names></name><name><surname>Ross</surname><given-names>R.P.</given-names></name><name><surname>Hill</surname><given-names>C.</given-names></name></person-group><article-title>Bacteriocins &#x02013; a viable alternative to antibiotics?</article-title><source>Nat Rev Microbiol</source><volume>11</volume><year>2013</year><fpage>95</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nrmicro2937</pub-id><pub-id pub-id-type="pmid">23268227</pub-id></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Lange-Starke</surname><given-names>A.</given-names></name><name><surname>Petereit</surname><given-names>A.</given-names></name><name><surname>Truyen</surname><given-names>U.</given-names></name><name><surname>Braun</surname><given-names>P.G.</given-names></name><name><surname>Fehlhaber</surname><given-names>K.</given-names></name><name><surname>Albert</surname><given-names>T.</given-names></name></person-group><article-title>Antiviral potential of selected starter cultures, bacteriocins and d,l-lactic acid</article-title><source>Food Environ Virol</source><volume>6</volume><year>2014</year><fpage>42</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1007/s12560-013-9135-z</pub-id><pub-id pub-id-type="pmid">24297091</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Ma&#x00142;aczewska</surname><given-names>J.</given-names></name><name><surname>Kaczorek-&#x00141;Ukowska</surname><given-names>E.</given-names></name><name><surname>W&#x000f3;jcik</surname><given-names>R.</given-names></name><name><surname>Krzysztof Siwicki</surname><given-names>A.</given-names></name></person-group><article-title>Antiviral effects of nisin, lysozyme, lactoferrin and their mixtures against bovine viral diarrhoea virus</article-title><source>BMC Vet Res</source><volume>15</volume><year>2019</year><fpage>318</fpage><pub-id pub-id-type="doi">10.1186/s12917-019-2067-6</pub-id><pub-id pub-id-type="pmid">31488163</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Starosila</surname><given-names>D.</given-names></name><name><surname>Rybalko</surname><given-names>S.</given-names></name><name><surname>Varbanetz</surname><given-names>L.</given-names></name><name><surname>Ivanskaya</surname><given-names>N.</given-names></name><name><surname>Sorokulova</surname><given-names>I.</given-names></name></person-group><article-title>Anti-influenza activity of a <italic>Bacillus subtilis</italic> probiotic strain</article-title><source>Antimicrob Agents Chemother</source><volume>61</volume><year>2017</year><comment>e00539-17</comment><pub-id pub-id-type="doi">10.1128/AAC.00539-17</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>T.</given-names></name><name><surname>Baindara</surname><given-names>P.</given-names></name><name><surname>Mandal</surname><given-names>S.M.</given-names></name></person-group><article-title>LPD-12, a promising lipopeptide to control COVID-19</article-title><source>Int J Antimicrob Agents</source><volume>57</volume><year>2020</year><fpage>106218</fpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.106218</pub-id><pub-id pub-id-type="pmid">33166692</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Manna</surname><given-names>S.</given-names></name><name><surname>Baindara</surname><given-names>P.</given-names></name><name><surname>Mandal</surname><given-names>S.M.</given-names></name></person-group><article-title>Fusion protein targeted antiviral peptides: fragment based drug design (FBDD) guided rational design of dipeptides against SARS-CoV-2</article-title><source>Curr Protein Pept Sci</source><volume>21</volume><year>2020</year><fpage>938</fpage><lpage>947</lpage><pub-id pub-id-type="doi">10.2174/1389203721666200908164641</pub-id><pub-id pub-id-type="pmid">32901582</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Thaden</surname><given-names>J.T.</given-names></name><name><surname>Maskarinec</surname><given-names>S.A.</given-names></name></person-group><article-title>When two for the price of one isn&#x02019;t a bargain: estimating prevalence and microbiology of bacterial co-infections in patients with COVID-19</article-title><source>Clin Microbiol Infect</source><volume>26</volume><year>2020</year><fpage>1602</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.09.002</pub-id><pub-id pub-id-type="pmid">32919069</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Parrill</surname><given-names>A.</given-names></name><name><surname>Tsao</surname><given-names>T.</given-names></name><name><surname>Dong</surname><given-names>V.</given-names></name><name><surname>Huy</surname><given-names>N.T.</given-names></name></person-group><article-title>SARS-CoV-2-induced immunodysregulation and the need for higher clinical suspicion for co-infection and secondary infection in COVID-19 patients</article-title><source>J&#x000a0;Microbiol Immunol Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jmii.2020.08.016</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Sohal</surname><given-names>S.</given-names></name><name><surname>Rodriguez-Nava</surname><given-names>G.</given-names></name><name><surname>Khabbaz</surname><given-names>R.</given-names></name><name><surname>Chaudry</surname><given-names>S.</given-names></name><name><surname>Musurakis</surname><given-names>C.</given-names></name><name><surname>Chitrakar</surname><given-names>S.</given-names></name></person-group><article-title>SARS-CoV2 and co-infections: a review of two cases</article-title><source>Case Rep Infect Dis</source><volume>2020</volume><year>2020</year><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1155/2020/8882348</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Manna</surname><given-names>S.</given-names></name><name><surname>Baindara</surname><given-names>P.</given-names></name><name><surname>Mandal</surname><given-names>S.M.</given-names></name></person-group><article-title>Molecular pathogenesis of secondary bacterial infection associated to viral infections including SARS-CoV-2</article-title><source>J&#x000a0;Infect Public Health</source><volume>13</volume><year>2020</year><fpage>1397</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1016/j.jiph.2020.07.003</pub-id><pub-id pub-id-type="pmid">32712106</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Langford</surname><given-names>B.J.</given-names></name><name><surname>So</surname><given-names>M.</given-names></name><name><surname>Raybardhan</surname><given-names>S.</given-names></name><name><surname>Leung</surname><given-names>V.</given-names></name><name><surname>Westwood</surname><given-names>D.</given-names></name><name><surname>MacFadden</surname><given-names>D.R.</given-names></name></person-group><article-title>Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis</article-title><source>Clin Microbiol Infect</source><volume>26</volume><year>2020</year><fpage>1622</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2020.07.016</pub-id><pub-id pub-id-type="pmid">32711058</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Ripa</surname><given-names>M.</given-names></name><name><surname>Galli</surname><given-names>L.</given-names></name><name><surname>Poli</surname><given-names>A.</given-names></name><name><surname>Oltolini</surname><given-names>C.</given-names></name><name><surname>Spagnuolo</surname><given-names>V.</given-names></name><name><surname>Mastrangelo</surname><given-names>A.</given-names></name></person-group><article-title>Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors</article-title><source>Clin Microbiol Infect</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.cmi.2020.10.021</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Kimmig</surname><given-names>L.M.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Gold</surname><given-names>M.</given-names></name><name><surname>Pettit</surname><given-names>N.N.</given-names></name><name><surname>Pitrak</surname><given-names>D.</given-names></name><name><surname>Mueller</surname><given-names>J.</given-names></name></person-group><article-title>IL-6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections</article-title><source>Front Med</source><volume>7</volume><year>2020</year><pub-id pub-id-type="doi">10.3389/fmed.2020.583897</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Risks and features of secondary infections in severe and critical ill COVID-19 patients</article-title><source>Emerg Microbe. Infect</source><volume>9</volume><year>2020</year><fpage>1958</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1080/22221751.2020.1812437</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.T.</given-names></name><name><surname>Zhang</surname><given-names>F.S.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>S.F.</given-names></name><name><surname>Ma</surname><given-names>S.</given-names></name></person-group><article-title>Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial</article-title><source>Intensive Care Med</source><volume>42</volume><year>2016</year><fpage>1018</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1007/s00134-016-4303-x</pub-id><pub-id pub-id-type="pmid">27043237</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Morrow</surname><given-names>L.E.</given-names></name><name><surname>Kollef</surname><given-names>M.H.</given-names></name><name><surname>Casale</surname><given-names>T.B.</given-names></name></person-group><article-title>Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial</article-title><source>Am J Respir Crit Care Med</source><volume>182</volume><year>2010</year><fpage>1058</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1164/rccm.200912-1853OC</pub-id><pub-id pub-id-type="pmid">20522788</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>J.M.</given-names></name><name><surname>Mercenier</surname><given-names>A.</given-names></name></person-group><article-title>Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria</article-title><source>Nat Rev Microbiol</source><volume>6</volume><year>2008</year><fpage>349</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/nrmicro1840</pub-id><pub-id pub-id-type="pmid">18345021</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J.Y.</given-names></name><name><surname>Young</surname><given-names>T.L.</given-names></name><name><surname>Eun</surname><given-names>J.K.</given-names></name><name><surname>Ji</surname><given-names>H.J.</given-names></name><name><surname>Min</surname><given-names>K.P.</given-names></name><name><surname>Cheol</surname><given-names>H.K.</given-names></name></person-group><article-title>Novel mechanisms of conferring broad protection against influenza by <italic>Lactobacillus casei</italic> lactic acid bacteria by mobilizing innate and adaptive immune cells (INC1P.354)</article-title><source>J&#x000a0;Immunol</source><volume>194</volume><year>2015</year></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>Y.J.</given-names></name><name><surname>Lee</surname><given-names>Y.T.</given-names></name><name><surname>Ngo</surname><given-names>V Le</given-names></name><name><surname>Cho</surname><given-names>Y.H.</given-names></name><name><surname>Ko</surname><given-names>E.J.</given-names></name><name><surname>Hong</surname><given-names>S.M.</given-names></name></person-group><article-title>Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection</article-title><source>Sci Rep</source><volume>7</volume><year>2017</year><fpage>17360</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17487-8</pub-id><pub-id pub-id-type="pmid">29234060</pub-id></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Bidossi</surname><given-names>A.</given-names></name><name><surname>De Grandi</surname><given-names>R.</given-names></name><name><surname>Toscano</surname><given-names>M.</given-names></name><name><surname>Bottagisio</surname><given-names>M.</given-names></name><name><surname>De Vecchi</surname><given-names>E.</given-names></name><name><surname>Gelardi</surname><given-names>M.</given-names></name></person-group><article-title>Probiotics <italic>Streptococcus salivarius</italic> 24SMB and Streptococcus oralis 89a interfere with biofilm formation of pathogens of the upper respiratory tract</article-title><source>BMC Infect Dis</source><volume>18</volume><year>2018</year><fpage>653</fpage><pub-id pub-id-type="doi">10.1186/s12879-018-3576-9</pub-id><pub-id pub-id-type="pmid">30545317</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Santagati</surname><given-names>M.</given-names></name><name><surname>Scillato</surname><given-names>M.</given-names></name><name><surname>Patan&#x000e8;</surname><given-names>F.</given-names></name><name><surname>Aiello</surname><given-names>C.</given-names></name><name><surname>Stefani</surname><given-names>S.</given-names></name></person-group><article-title>Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens</article-title><source>FEMS Immunol Med Microbiol</source><volume>65</volume><year>2012</year><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">22243526</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Waki</surname><given-names>N.</given-names></name><name><surname>Matsumoto</surname><given-names>M.</given-names></name><name><surname>Fukui</surname><given-names>Y.</given-names></name><name><surname>Suganuma</surname><given-names>H.</given-names></name></person-group><article-title>Effects of probiotic <italic>Lactobacillus brevis</italic> KB290 on incidence of influenza infection among schoolchildren: an open-label pilot study</article-title><source>Lett Appl Microbiol</source><volume>59</volume><year>2014</year><fpage>565</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1111/lam.12340</pub-id><pub-id pub-id-type="pmid">25294223</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Kinoshita</surname><given-names>T.</given-names></name><name><surname>Maruyama</surname><given-names>K.</given-names></name><name><surname>Suyama</surname><given-names>K.</given-names></name><name><surname>Nishijima</surname><given-names>M.</given-names></name><name><surname>Akamatsu</surname><given-names>K.</given-names></name><name><surname>Jogamoto</surname><given-names>A.</given-names></name></person-group><article-title>The effects of OLL1073R-1 yogurt intake on influenza incidence and immunological markers among women healthcare workers: a randomized controlled trial</article-title><source>Food Funct</source><volume>10</volume><year>2019</year><fpage>8129</fpage><lpage>8136</lpage><pub-id pub-id-type="doi">10.1039/c9fo02128k</pub-id><pub-id pub-id-type="pmid">31738351</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>S.E.</given-names></name><name><surname>Lamson</surname><given-names>D.M.</given-names></name><name><surname>Kirsten</surname><given-names>S.</given-names></name><name><surname>Walsh</surname><given-names>T.J.</given-names></name></person-group><article-title>Human rhinoviruses</article-title><source>Clin Microbiol Rev</source><volume>26</volume><year>2013</year><fpage>135</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1128/CMR.00077-12</pub-id><pub-id pub-id-type="pmid">23297263</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Tapiovaara</surname><given-names>L.</given-names></name><name><surname>Kumpu</surname><given-names>M.</given-names></name><name><surname>M&#x000e4;kivuokko</surname><given-names>H.</given-names></name><name><surname>Waris</surname><given-names>M.</given-names></name><name><surname>Korpela</surname><given-names>R.</given-names></name><name><surname>Pitk&#x000e4;ranta</surname><given-names>A.</given-names></name></person-group><article-title>Human rhinovirus in experimental infection after peroral <italic>Lactobacillus rhamnosus</italic> GG consumption, a pilot study</article-title><source>Int Forum Allergy Rhinol</source><volume>6</volume><year>2016</year><fpage>848</fpage><lpage>853</lpage><pub-id pub-id-type="doi">10.1002/alr.21748</pub-id><pub-id pub-id-type="pmid">26990147</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Kumpu</surname><given-names>M.</given-names></name><name><surname>Kekkonen</surname><given-names>R.A.</given-names></name><name><surname>Korpela</surname><given-names>R.</given-names></name><name><surname>Tynkkynen</surname><given-names>S.</given-names></name><name><surname>J&#x000e4;rvenp&#x000e4;&#x000e4;</surname><given-names>S.</given-names></name><name><surname>Kautiainen</surname><given-names>H.</given-names></name></person-group><article-title>Effect of live and inactivated <italic>Lactobacillus rhamnosus</italic> GG on experimentally induced rhinovirus colds: randomised, double blind, placebo-controlled pilot trial</article-title><source>Benef Microbe</source><volume>6</volume><year>2015</year><fpage>631</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.3920/BM2014.0164</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Kumpu</surname><given-names>M.</given-names></name><name><surname>Lehtoranta</surname><given-names>L.</given-names></name><name><surname>Roivainen</surname><given-names>M.</given-names></name><name><surname>R&#x000f6;nkk&#x000f6;</surname><given-names>E.</given-names></name><name><surname>Ziegler</surname><given-names>T.</given-names></name><name><surname>S&#x000f6;derlund-Venermo</surname><given-names>M.</given-names></name></person-group><article-title>The use of the probiotic <italic>Lactobacillus rhamnosus</italic> GG and viral findings in the nasopharynx of children attending day care</article-title><source>J&#x000a0;Med Virol</source><volume>85</volume><year>2013</year><fpage>1632</fpage><lpage>1638</lpage><pub-id pub-id-type="doi">10.1002/jmv.23623</pub-id><pub-id pub-id-type="pmid">23794458</pub-id></element-citation></ref><ref id="bib67"><label>67</label><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Guillemard</surname><given-names>E.</given-names></name><name><surname>Tondu</surname><given-names>F.</given-names></name><name><surname>Lacoin</surname><given-names>F.</given-names></name><name><surname>Schrezenmeir</surname><given-names>J.</given-names></name></person-group><article-title>Consumption of a fermented dairy product containing the probiotic <italic>Lactobacillus casei</italic> DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial</article-title><source>Br J Nutr</source><volume>103</volume><year>2010</year><fpage>58</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1017/S0007114509991395</pub-id><pub-id pub-id-type="pmid">19747410</pub-id></element-citation></ref><ref id="bib68"><label>68</label><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J.A.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Hong</surname><given-names>S.K.</given-names></name><name><surname>Lee</surname><given-names>D.H.</given-names></name><name><surname>Lee</surname><given-names>S.W.</given-names></name><name><surname>Song</surname><given-names>C.S.</given-names></name></person-group><article-title>Oral intake of <italic>Lactobacillus rhamnosus</italic> M21 enhances the survival rate of mice lethally infected with influenza virus</article-title><source>J&#x000a0;Microbiol Immunol Infect</source><volume>49</volume><year>2016</year><fpage>16</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.jmii.2014.07.011</pub-id><pub-id pub-id-type="pmid">25304268</pub-id></element-citation></ref><ref id="bib69"><label>69</label><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Hu</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name></person-group><article-title><italic>Bacillus subtilis</italic> and surfactin inhibit the transmissible gastroenteritis virus from entering the intestinal epithelial cells</article-title><source>Biosci Rep</source><volume>37</volume><year>2017</year><pub-id pub-id-type="doi">10.1042/BSR20170082</pub-id></element-citation></ref><ref id="bib70"><label>70</label><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>R.B.</given-names></name><name><surname>Woodfolk</surname><given-names>J.A.</given-names></name><name><surname>Borish</surname><given-names>L.</given-names></name><name><surname>Steinke</surname><given-names>J.W.</given-names></name><name><surname>Patrie</surname><given-names>J.T.</given-names></name><name><surname>Muehling</surname><given-names>L.M.</given-names></name></person-group><article-title>Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection &#x02013; a randomised controlled trial</article-title><source>Benef Microbe</source><volume>8</volume><year>2017</year><fpage>207</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.3920/BM2016.0160</pub-id></element-citation></ref></ref-list></back></article>